Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season.
Feuchtinger
Tobias
T
Bartz
Holger
H
von Berg
Andrea
A
Riedinger
Frank
F
Brauburger
Jens
J
Stenglein
Stephan
S
Wahn
Ulrich
U
Schauer
Uwe
U
D000293:Adolescent; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D002675:Child, Preschool; D003713:Dendritic Cells / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D000069444:Omalizumab; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology* / Q000628:therapy*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab